Edward Fruitman, MD
1451 Broadway
Hewlett, NY 11557
(516) 295-4867

TMS Can Help Treat Root Causes of Depression & Anxiety

Dr. Edward Fruitman, Medical Director of South Shore Neuropsychiatric Center offers innovative genetically based treatment options for Depression and Anxiety. At South Shore Neuropsychiatric Center we offer a simple test that gives insight into our patients’ specific genetic profile which enables Dr. Fruitman to optimize medication regimen and/or offer alternative treatment options.

Recent studies suggest that early life experiences in combination with genetic predispositions are major contributors to treatment resistant anxiety and depression.  The amygdala is a region of the brain responsible for emotion regulation while the prefrontal cortex (PFC) is responsible for emotion processing. Fear inducing cues increase amygdala activity and cause the physiological responses to anxiety. The PFC regulates the amygdala effect by inhibiting autonomic and endocrine responses to stressors. In essence, the PFC controls the extent of an emotional response. Individuals that experience heightened anxiety and depressive symptoms are shown to have an inability to control and habituate responses to stressors.  Studies suggest that genetic factors may contribute to this effect. Researchers found that in “subjects carrying a substituted methionine in the BDNF gene, fear doesn’t extinguish as readily in response to repeated nonthreatening cues; in those with a valine, it extinguishes more easily. Using neuroimaging, the authors showed that polymorphism carriers exhibited more amygdala and less PFC activity with subsequent cue presentations.”  In these individuals the PFC is dormant and individuals may not respond to psychotherapy or medication.

Transcranial Magnetic Stimulation Therapy (TMS) is a noninvasive treatment option for individuals suffering from treatment resistant anxiety and depression.  TMS stimulates the PFC using noninvasive magnetic energy, which over time provides relief to depression and anxiety symptoms. Dr. Edward Fruitman is the pioneer provider of Transcranial Magnetic Stimulation (TMS) Therapy in the Five Towns area. Dr. Fruitman has successfully treated patients suffering from anxiety and depression with TMS since 2010.

PROBLEM: ADDED COST FOR MEDICAL PATIENTS WITH TREATMENT RESISTANT MAJOR DEPRESSION SOLUTION: TRANSCRANIAL MAGNETIC STIMULATION?

Behavioral Healthcare/ December 4, 2013

By Alison Knopf

neurostar-infoTranscranial Magnetic Stimulation (TMS) may be the best way to help patients with treatment-resistant major depression (TRMD) – people who have tried antidepressants at least once for the appropriate amount of time on the appropriate dose, according to Pete Mumma, Administrative Director of the Behavioral Health Service Line in the Department of Psychiatry at Lancaster General Health in Lancaster, Pennsylvania. But that doesn’t mean it’s easy to “sell” the TMS device to financial people in your institution.

Here’s how Mumma did it: 9.1 percent of the population has depression, and .05 percent has TRMD. These people are “superutilizers,” who consume 18 percent of a health system’s uncompensated or undercompensated spending. “It’s unsustainable,” he said. “We expect people who have extreme needs to be treated in pathway models that don’t meet their needs – what will we do with these patients, not just from a mental health perspective, but from a total medical perspective?”

For example, an individual with TRMD who also has cardiac disease or cancer is going to be very complicated to treat. “Any medical provider who is helping patients with TRMD is going to bump up against some or all of their issues,” said Mumma. Symptoms such as lack of energy, lack of concentration, and sleep problems create further distractions for the patient, he said. The recommendations of the cardiologist or oncologist won’t go as far as they would if the patient didn’t have depression.

The impact of mental health problems on physical treatment is more relevant now than it was in the past because of the way health systems are being reimbursed, said Mumma, citing in particular the penalty for readmissions within 30 days. If a patient fails cardiac treatment – perhaps because he didn’t exercise, something that is notably difficult for people with depression – and needs to be readmitted, that’s a ding to the hospital’s bottom line. “So cardiologists and every other doctor wants to make sure they eliminate barriers to good outcomes,” he said. Mental problems that make it difficult to follow through with physician recommendations are suddenly seen as very important – a good thing for both patients and the health care system.

“We can spend a little money up front to treat the depression, and the patient’s cardiac care goes farther, faster,” said Mumma.

The treatment

Typically, patients start with a daily course of treatment, which takes about 37 minutes. This would go on for four to six weeks. The treatment is painless and requires no sedation. Once the initial course is done, some patients may come back for a maintenance treatment. The treating provider will determine the exact treatment protocol and any maintenance needed.

Medications

The first line of treatment for depression is medication, but people with TRMD are patients for whom medication isn’t working. On the system side, the clinical benefit is important, but on the patient side, it’s crucial. “The tragic thing is these patients aren’t getting better,” said Mumma of TRMD.

Doing depression care differently – what Mumma is suggesting is avoiding the “shotgun approach” that most depression patients who have tried one medication after another have experienced. At Lancaster, before selecting a medication, the psychiatry department does “pharmacogenetic” testing via a cheek swab to at least narrow down the type of medication to try in the first place. “But many patients get agent after agent, and have had no other options over their lifetime.” Now, at least patients who have failed one course of medication with an appropriate dose and duration have another option.

“Through medications, we’re trying to light up some parts of the brain and quiet others,” said Mumma. That’s the same thing that TMS does – the magnet near the head “reaches deep into the amygdala, which scientists think is responsible for mood,” he said. “Instead of washing the brain with chemicals, this seems to isolate the problem.” Many patients continue to take medications while getting TMS but find they can reduce their medications over time, he added.

Another issue is the cost of medications. Abilify, the medication used for treatment-resistant major depression, is very expensive, said Mumma. “The health plan might be paying more than $1,000 per month” for Abilify, he said. “Add to that the costs of Celexa or other medications, plus the medication management.”

Tracking medical costs

Mumma also has scrutinized the literature, finding that one study showed that the most costly expense to employers was depression, at a cost of more than $350,000 per thousand employees. That isn’t only medical costs, of course, but aggregated costs of medical treatment, pharmacy, absenteeism, and “presenteeism” – in which employees are still at work but unable to function. “If we were to do depression care differently, that’s a huge savings,” said Mumma.

Patients paying

In clinical trials, suicidality was four times higher in the placebo group than the TMS group, said Mumma. (In the clinical trials, TMS was compared to sham TMS, not compared to medication.)

Major depression is a devastating disease for people who don’t get better, and 40 percent of the patients experience remission, said Mumma, who is not compensated by Neuronetics.

The big question is whether TMS is going to be as effective as electroconvulsive therapy (ECT), said Mumma. Clearly TMS is much more appealing to patients. “ECT is scary as hell, and it has ugly side effects like memory loss,” he said. ECT is effective, but many studies are showing comparable results for people with TMS, said Mumma.

“Nobody’s using the word, ‘cure,’” said Mumma. But TMS is different from medications, he said. TMS is non-medication based treatment, so there are no drug-drug interactions. “It’s difficult to get off of antidepressants once you get on, and antidepressants are basically a band-aid for a problem – just symptom improvement, not managing the illness.”  TMS does allow patients to return to functionality with fewer side effects than medication, said Mumma.

NEBA: First Brain-Wave Test for ADHD Approved by FDA

The US Food and Drug Administration (FDA) has recently approved the first brain-wave test to help diagnose attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years, the agency announced.

The device, called Neuropsychiatric EEG-Based Assessment Aid (NEBA) System, is a  noninvasive test, based on electroencephalogram (EEG) technology. The system computes the ratio of theta and beta brain waves in 15 to 20 minutes, which can be used to help diagnose/or reverse diagnose ADD/ADHD in children and adolescents. Children and adolescents with ADHD have a higher theta-beta ratio than those who do not have the disorder.

Together with a complete medical and psychological workup, the NEBA System can help confirm a diagnosis of ADHD or a decision to focus further testing on ADHD or other conditions with similar symptoms, according to the FDA.

“The NEBA System along with other clinical information may help healthcare providers more accurately determine if ADHD is the cause of a behavioral problem,” Christy Foreman, director of the Office of Device Evaluation at the FDA’s Center for Devices and Radiological Health, said in a news release.

The agency based its decision to approve the NEBA System in part on a clinical study of 275 children and adolescents with attention or behavioral issues. Clinicians evaluated all of them using the new brain-wave test along with standard diagnostic protocols and physical exams. An independent panel of ADHD experts reviewed the findings to determine whether each patient satisfied the criteria for ADHD or another condition. The study showed that adding the brain-wave test to a clinical assessment helped clinicians make a more accurate ADHD diagnosis than if they had performed only the clinical assessment.

The NEBA System is made by NEBA Health, in Augusta, Georgia.

The NEBA System is now available at South Shore Neuropsychiatric Center in Hewlett, NY. Under the supervision of Medical Director, Edward Fruitman, MD, children and adolescents can be tested and the risk of ADD/ADHD misdiagnosis will be decreased exponentially. For more information call the office of Dr. Edward Fruitman (516)295-4867.

TMS Could Help Treat Chronic Dizziness

Researchers from the Johns Hopkins University School of Medicine believe that they have located a specific site in the human brain that could be one of the sources of dizziness and spatial disorientation.

While dizziness can also be linked to damage to the inner ear, or to other senses such as vision, neurology instructor Dr. Amir Kheradmand and his colleagues report that they have discovered a region of the brain that plays a vital role in our subconscious awareness of which way is up and which way is down.

Their study, which appears online in the journal Cerebral Cortex, found that some causes of dizziness, unsteadiness and “floating” could be linked to that region in the parietal cortex.

The study authors opted to focus their analysis on the right parietal cortex, as research on stroke victims with balance problems has suggested that damage to that region of the brain was directly involved with upright perception.

They recruited eight healthy subjects, placing each in a dark room and showing them lines that were illuminated on a screen. Dr. Kheradmand’s team then had the study participants report the orientation of each line by rotating a dial to the left, the right, or straight ahead.

The subjects then received (TMS) – an FDA-approved treatment for depression and which “painlessly and noninvasively delivers electromagnetic currents to precise locations in the brain.”

Each individual had a TMS coil placed behind the ear and against the scalp across the right parietal lobe. The subjects received 600 electromagnetic pulses over the course of 40 seconds, and at the end of each session, they were asked a second time to show the researchers which way the illuminated line was positioned. At the end of the study, all of the subjects reported that his or her sense of being upright had been altered in the same way after TMS was administered in the same location in the parietal cortex.

According to Kheradmand, his team’s findings suggest that this form of stimulation could be used to treat chronic dizziness. “If we can disrupt upright perception in healthy people using TMS, it might also be possible to use TMS to fix dysfunction in the same location in people with dizziness and spatial disorientation,” he said.

FDA approves TMS device to relieve migraine pain

FoxNews.com

694940094001_1409784734001_640-brain.jpgThose who suffer from debilitating migraines may soon be able receive an outpatient procedure that can help alleviate their pain, as reported by Nature World News.

The U.S. Food and Drug Administration (FDA) recently approved a TMS device for people who suffer from migraines that are preceded by an aura – characterized by a tingling sensation in the extremities and flashes of light or blind spots in a person’s vision. The device uses magnetic energy to stimulate the occipital cortex – an area of the brain involved in visual processing – in order to alleviate migraine pain.

In a trial conducted by the FDA, 201 migraine sufferers tested the device when they experienced head pain. Overall, 38 percent of patients using the device experienced relief from migraine pain within two hours, compared to just 17 percent of people who were given a fake version of the device.

While the TMS has not been proven to completely eliminate all migraine symptoms, it does help relieve migraine pain. The FDA noted that the device doesn’t provide relief for other symptoms of migraines, including  sensitivity to light, sensitivity to sound and nausea.

Data Published in CNS Spectrums Indicate Acute Transcranial Magnetic Stimulation (TMS) with NeuroStar TMS Therapy® Improves Quality of Life in Patients with Depression

MALVERN, Pa., Sept. 16, 2013 /PRNewswire/ — Neuronetics, Inc., today announced that results of a naturalistic, observational study from 42 clinical trial sites in the United States, which examined the efficacy of acute treatment with NeuroStar TMS Therapy® in patients with Major Depressive Disorder (MDD), were published in the July 2013 issue of CNS Spectrums. In the study, patients who experienced persistent symptoms of MDD without benefit from concurrent antidepressant pharmacotherapy reported statistically and clinically meaningful improvement in quality of life (QOL) symptoms and functional status following acute treatment with NeuroStar TMS Therapy.  Acute efficacy results of this trial were previously reported, showing statistically significant improvement from baseline in depression symptoms including 58% response and 37% remission rates as rated by the clinician using the CGI-Severity of Illness scale under conditions of general clinical use (Carpenter, et al, 2012).

MDD is a debilitating condition in which nearly two-thirds of patients do not benefit adequately from antidepressant medications, and continue to experience life-altering symptoms and functional impairment.

“The publication of these findings is an important validation that NeuroStar TMS Therapy is effective in improving quality of life measures during acute treatment of MDD, particularly in patients with greater disease severity who have not benefitted from treatment with oral antidepressant medication,” said Philip Janicak, M.D., first author, Professor of Psychiatry at Rush UniversityMedical Center. “Patients reported improvement in QOL outcomes after just six weeks of treatment with NeuroStar TMS, which is faster than results we typically see with pharmacotherapy. These data offer hope to people living with MDD and reinforce TMS as a viable treatment option that induces symptom relief and improves overall well-being.”

The published observational study, entitled “Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Quality of Life Outcome Measures in Clinical Practice”, involved 307 outpatients across 42 clinical TMS practice sites in the United States with a primary diagnosis of MDD who had failed to benefit from  antidepressant medication. A recurrent course of illness was reported in 93 percent of patients and 44 percent had previously been hospitalized for depression. A significant level of treatment resistance was present.

At the end of the acute phase of NeuroStar TMS treatment, statistically significant improvements across physical health and mental health components variables were observed, as measured by the Short Form 36-Item Questionnaire (SF-36). Severely depressed patients experienced the most robust improvement in a relatively short time frame (six weeks). The largest treatment effects were observed on those subscale scores associated with improvements in mental health and social functioning. In addition, 37 percent (N=114) of study patients achieved remission during acute NeuroStar treatment and experienced a superior improvement in QOL compared with non-remitters. Patients with moderately severe to severe depression had the most robust improvement in QOL.

The vitality, social functioning, role-emotional, and mental health perceptions subscales of SF-36 showed a statistically significant improvement of 12-14.8 points or 1.2-1.5 standard deviations (SDs) in the normed score. The mean mental component summary (MCS) score improved by 16.8 points to 33.5 (+/- 15.06), which is comparable to previous studies showing an improvement in the MCS scores following nine months of treatment with paroxetine (15.8), fluoxetine (15.1), or sertraline (17.4). The subpopulation of remitters showed a much more robust improvement of 27.4 to 30.9 points, reaching scores that are close to the general population norms and are only 0.13 to 0.55 SDs lower.

While the Factors Influencing Depression Endpoints Research (FINDER) Study, a European, prospective, observational trial in 3,468 patients, reported that severely depressed patients had significantly worse SF-36 MCS outcomes, the CNS Spectrums’published study demonstrated that acute NeuroStar TMS treatment produced a pronounced QOL improvement in moderately severely- and severely-ill patients compared with the mildly- and moderately-ill groups.

About NeuroStar TMS Therapy®
Neuronetics’ NeuroStar TMS Therapy System was cleared by the FDA in October 2008 for the treatment of Major Depressive Disorder (MDD). NeuroStar TMS Therapy is indicated for the treatment of MDD in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. NeuroStar TMS Therapy is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation. It stimulates nerve cells in an area of the brain that has been linked to depression by delivering highly-focused MRI-strength magnetic field pulses.

In a controlled trial, patients treated with active NeuroStar TMS Therapy received greater than 3 times the improvement in depressive symptoms compared to placebo at four weeks (MADRS, -7.1 vs -2.1, P=0.0006).  The treatment is available by prescription and typically administered daily for 4-6 weeks.

About Depression
Depression is a serious illness that affects about 20 million Americans annually. People with depression may experience a range of physically and emotionally debilitating symptoms, including anxiousness, sadness, irritability, fatigue, changes in sleep patterns, loss of interest in previously enjoyable activities and digestive problems. It is estimated that about four million patients do not benefit from standard treatments for depression, even after repeated treatment attempts.

About the Study
Forty-two clinical TMS practice sites across the United States treated 307 outpatients with a primary diagnosis of MDD and persistent symptoms despite adequate antidepressant pharmacotherapy. Treatment parameters were based on individual clinical considerations and followed the labeled procedures for use of the NeuroStar TMS Therapy System. Functional status was ascertained using the Medical Outcome Study Short-Form Health Survey (SF-36), comprised of eight subscales that measure physical and role functioning: bodily pain, general health, vitality, social and role functioning, and mental health. The physical component summary (PCS) score and a mental component summary (MCS) score integrate information from all eight of the subscales. Patient-reported QOL was also characterized using the EuroQol 5-Dimension Questionnaire (EQ-5D), which contains five dimensions measuring the degree of impairment in the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

Patient-reported outcome measures of functional status and QOL were obtained at baseline prior to the initial TMS treatment, and again at the end of acute treatment.

Magnetic fields help to combat depression

Aisha Dow (Syndey Morning Herald)

A pioneering medical treatment using intense magnetic fields is achieving dramatic results for patients with drug-resistant chronic depression.

After living with depression her entire life, Jan Steele, 57, said undergoing magnetic stimulation had been like winning the lottery. This weekend she is driving to Canberra for a weekend away with her husband. Before her treatment, she would often spend Saturday and Sunday in bed.

“The enjoyment I get out of life is outstanding now, even if it’s just staying home and watching TV,” she said.

Targeted at the approximately 30 per cent of people who have treatment-resistant depression, TMS involves the use of an extremely focused magnetic field.

As the patient sits awake in an armchair, a wand containing a plastic-coated coil is placed close to their scalp – creating a magnetic field that stimulates activity in the brain. The treatment takes about four to six weeks and involves about 20 or 30 daily sessions lasting 45 minutes, although researchers have been successfully trialling a six-day treatment.

Centre deputy director Paul Fitzgerald said they believed TMS increased activity between areas of the brain involved in control of mood and emotion.

He said patients could remain depression-free for several months or even several years before they had to return for further sessions. “If they get better the first time, more than 90 per cent of people will respond again if you treat them,” Professor Fitzgerald said.

Chair of Psychiatry at Deakin University Michael Berk said TMS was one of the safest treatments available in the field of psychiatry. But like other depression treatments, including lithium and electroconvulsive therapy, he said researchers do not fully understand how it works, and why it works only in some people.

“There’s no [depression] treatment that works for everybody and we don’t have ways of predicting who will benefit from what treatment,” he said.

Experts at the Monash Alfred Psychiatry Research Centre are studying these unanswered questions and also the possibility TMS may treat other conditions, including schizophrenia and autism.

Until then, Jan Steele remains in remission. Depression, she said, was like carrying a wet blanket on your shoulders – and that weight has been lifted.

Ketamine’s Efficacy Validated in Major Refractory Depression

Caroline Cassels (Medscape.com)

Ketamine is a rapid, effective treatment for patients with treatment-resistant depression, new research shows.

The study showed that a single intravenous dose of ketamine, a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, improved depression in 64% of patients within 24 hours of administration vs 28% of patients who received the anesthetic midazolam.

“Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression,” the investigators, with first author James Murrough, MD, assistant professor of psychiatry and neuroscience and associate director of the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai, in New York City, write.

Reported in April 2013 at the Anxiety and Depression Association of America 33rd Annual Conference and covered by Medscape Medical News at that time, the results of 2-site, parallel-arm, randomized placebo-controlled study were published online August 28 in the American Journal of Psychiatry.

Promise of New Therapies

The study, which the researchers note is the largest to date to test the antidepressant effects of ketamine, included 73 participants with treatment-resistant major depression. Patients were randomly assigned in a 2:1 ratio to receive IV ketamine (n = 47) or midazolam (n = 25).

The study’s primary outcome was change in depression severity 24 hours after drug administration, as measured by the Montgomery-Ǻsberg Depression Rating Scale (MADRS).

Depression scores were not significantly different between treatment groups at 7 days.The researchers report that the likelihood of response at 24 hours was greater with ketamine than with midazolam (odds ratio, 2.18; 95% confidence interval, 1.21 – 4.14), with response rates of 64% and 28%, respectively.

Side effects associated with ketamine infusion included dissociative symptoms immediately following administration in 8 patients (17%). However, these side effects resolved by 2 hours postinfusion. In addition, for 2 patients, ketamine infusion was terminated due to significant changes in blood pressure.

The researchers note that more research is needed to identify strategies to prolong and maintain ketamine’s initial antidepressant response and to determine the drug’s long-term safety profile.

In an accompanying editorial, A. John Rush, MD, Duke–National University of Singapore Graduate Medical School in Singapore, writes that study does not validate a new treatment but rather points to a promising lead for new therapeutic development.

“While insufficient to recommend a wholesale change in practice presently, these results certainly provide substantial hope for patients with treatment-resistant depression, insight into the biology of this condition, and a major obligation by clinician scientists and funding agencies to answer this next set of important clinical questions for our patients with refractory depression,” Dr. Rush writes.

 

REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION OFFERS RELIEF FROM DEPRESSION

Umesh Isalkar, TNN Jul 28, 2013

Rakesh used to feel low. Soon he lost interest in his job. He took to alcohol to feel better and things kept going downhill after his wife walked out. When he approached doctor for treatment of depression, he had already spent two years in depression.

Today, Rakesh has almost recovered and leading a normal and productive life. Thanks to a new treatment modality called repetitive transcranial magnetic stimulation (rTMS). Rakesh is just one of many suffering from depression and one of the few who have had his depression treated with rTMS Therapy.

According to WHO ( World Health Organization) report depression is going to be second leading cause for disability. The problem however is not the illness but lack of awareness and stigma attached to it.

“Depression if not treated can last for more than a year. Treatment is necessary as depression can lead to professional, family, financial, and physical health related complications including suicide,” said psychiatrist Swapnil Deshmukh of Shreeyash Hospital who has treated Rakesh with rTMS.

Various types of treatment modalities are available depending on severity of illness including cognitive behavioural therapy (CBT), medicine, electro convulsive therapy (ECT), and latest – rTMS ( re-petitive Transcranial magnetic stimulation). All these are standard, well proved and accepted worldwide -FDA approved treatment modalities.

“Around 20% of cases are mild and can be treated with CBT itself but remaining requires medications in addition to counselling. Around 30 to 40% of depression cases can be severe, resistant to treatment.

“rTMS is a recent treatment modality in depression and other psychiatric illness in which magnetic waves can directly stimulate affected- less functioning brain areas non-invasively. It is considered to be safest, non-medicine dependent, cost effective treatment modality getting very popular in west. Combination of both rTMS and medication and therapy work best,” Deshmukh said.

For more information about our TMS services please contact us at South Shore Neuropsychiatric Center (516)295-4867

KETAMINE AND DEPRESSION

by Alexis King

DEPRESSION: Depression can come in many forms, but when the symptoms begin to interfere with people’s daily lives these feelings become an illness. Signs of depression include feelings of hopelessness or guilt, loss of interest in activities that used to be enjoyable, thoughts of suicide, and many more. Some people have minor bouts of depression, but major depressive disorder can be disabling. Other forms of depression are postpartum depression, which occurs after giving birth, and seasonal affective disorder, which comes on during the winter months due to lack of natural sunlight. Medications and psychotherapy may help to alleviate depression symptoms, but are ineffective in helping some individuals.

KETAMINE: The drug ketamine was first developed in 1963 to be used as an anesthetic in humans as well as animals. When used for medical purposes, ketamine comes as a liquid that is injected into patients and is chemically similar to PCP. Although doctors and veterinarians continue to administer the drug as an anesthetic, ketamine is also used recreationally as a “street drug.” Typically snorted or ingested in powder form, ketamine has been known to cause dream-like states and hallucinations. When taken in large amounts ketamine can cause an effect called the “K-hole” in which people experience an inescapable, often terrifying out-of-body experience.

MEDICAL BREAKTHROUGH: A new study, conducted by researchers at the Baylor College of Medicine in Houston and Mount Sinai School of Medicine in New York, shows that the experimental party drug, ketamine, can alleviate depression symptoms in just hours. The drug was shown to quickly reduce depression in participants after just one 40-minute IV dose. Most medications available today can take days, if not weeks, to reduce symptoms. The drug also has long-lasting results. After one week, 46 percent of the ketamine-assigned patients still reported reduced depression symptoms after taking the ketamine, compared to 18 percent in the placebo group. Although the ketamine has obvious benefits, it is still a hallucinogenic drug that can be very dangerous if not used under the supervision of a trained medical doctor.

For more information about the services we offer, please visit us at South Shore Neuropsychiatric Center.